Learning Goals Immunotherapies in BCell Malignancies Available Immunotherapies OS in MM Poor Outcome in HighRisk Myeloma Immunotherapy Potential for Success Without a Targetable Molecular Mutation ID: 719176
Download Presentation The PPT/PDF document "Harnessing the Immune System: Mechanism ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell MalignanciesSlide2
Learning GoalsSlide3
Immunotherapies in B-Cell MalignanciesSlide4
Available ImmunotherapiesSlide5
OS in MMSlide6
Poor Outcome in High-Risk MyelomaSlide7Slide8
Immunotherapy
Potential for Success Without a Targetable Molecular MutationSlide9
Available ImmunotherapiesSlide10
Monoclonal Antibodies Approved for MMSlide11
Elotuzumab and DaratumumabSlide12
DaratumumabSlide13
ElotuzumabSlide14
Daratumumab
Potential MOASlide15
Daratumumab MonotherapyPhase 2 Study, ≥ 3 Lines of Prior TherapySlide16
Daratumumab in CombinationSlide17
CASTOR StudyDaratumumab + Bor/Dex vs Bor/DexSlide18
CASTOR StudyEfficacy Endpoints and IRRsSlide19
POLLUXDaratumumab + Len/Dex vs Len/DexSlide20
ElotuzumabMOASlide21
ELOQUENT-2Elotuzumab + Len/Dex vs Len/DexSlide22
ELOQUENT-2Slide23
Therapies in DevelopmentAntibodiesSlide24
Antibody Drug ConjugatesSlide25
Brentuximab VedotinSlide26
AETHERABrentuximab Vedotin as Consolidation Therapy After ASCT in Patients With HLSlide27
Other ADCs in Development for MMSlide28
T-Cell Receptors
Activating and InhibitorySlide29Slide30
Checkpoint Inhibitors in HL Slide31
Checkpoint Inhibitors in MMSlide32
Structure of Chimeric Antigen Receptors Slide33
Clinical Trials With CAR-T Cells in MMSlide34
CAR-T Cell Therapy Slide35
Cytokine Release Syndrome (CRS)Slide36
Response to Tocilizumab in 2 PatientsSlide37
Bispecific T-Cell EngagersSlide38
Patient-Specific Dendritic Cell/MM Cell Fusion Vaccines Postautologous TransplantSlide39
Response Rates After VaccinationSlide40
Future of Immunotherapeutic Strategies in B-Cell MalignanciesSlide41
ConclusionsSlide42
AbbreviationsSlide43
Abbreviations (cont)Slide44
Abbreviations (cont)Slide45
Abbreviations (cont)